Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
about
In situ imaging of metals in cells and tissuesCoordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseCellular up-regulation of Nedd4 family interacting protein 1 (Ndfip1) using low levels of bioactive cobalt complexes.Cobalt derivatives as promising therapeutic agentsEffects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.Application of metal coordination chemistry to explore and manipulate cell biology.Identification of compounds selectively killing multidrug-resistant cancer cellsThe use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells.Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells.A novel water soluble ligand bridged cobalt(II) coordination polymer of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (isonicotinic) hydrazone: evaluation of the DNA binding, protein interaction, radical scavenging and anticancer activity.Cobalt(III) as a stable and inert mediator ion between NTA and His6-tagged proteins.Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design.The influence of the ancillary ligand on the potential of cobalt(iii) complexes to act as chaperones for hydroxamic acid-based drugs.Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery.Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands.Cobalt(III)-Mediated Permanent and Stable Immobilization of Histidine-Tagged Proteins on NTA-Functionalized Surfaces.Reversible magnetogenic cobalt complexesDNA Interaction Studies of a Cobalt(II) Mixed-Ligand Complex Containing Two Intercalating Ligands: 4,7-Dimethyl-1, 10-Phenanthroline and Dipyrido[3,2-a:2′,3′-c]phenazine
P2860
Q28662002-FB5DEE04-4DE3-4B8A-B2D8-EC228BD33B86Q33870879-46FED5E1-B645-46D8-8377-16075EF9A48AQ34624481-502A4603-A98A-45A1-859F-DD88A11CC1E7Q36756033-1B10EC9B-E813-4545-85F3-B8AA321E4565Q37304068-833DAA29-AED9-4A3A-A9BE-465CFD75D060Q37387617-7FC0048E-B4B5-4111-8D92-7F93A8CB4689Q37440253-15E87E5A-AE1B-4BAC-9074-34D3FAECF5ADQ38096196-F2406A8A-1399-49D6-9D52-A48B6CFB4974Q38759894-22CA557A-8473-4482-8E83-8EEC01893065Q38827618-8620DE10-A4A9-4C89-B21B-8A496F93AD17Q39392668-44F60C69-DD35-4CB7-907E-1B5CE23BC141Q41838247-40F69C9C-2A77-4342-B8DA-EF7DDF81AB43Q42576712-103CFC79-EF75-49D9-842B-8ACA7ECA50F5Q50109337-1CAE98F0-E741-4873-96FD-9F27CF9B0734Q50803523-6345E969-C28F-4F3B-9B27-4DFDBF67E722Q50863499-D6AF4E9A-338C-4DDD-89C7-0589D74F3622Q53800140-A6AC5ECA-B53B-4B19-8A93-363344FD00DCQ56434351-3469C65E-FD69-404A-949D-55114344CEE1Q58996587-9BD9F399-DD95-4CF6-A73E-1C0D522F9C66
P2860
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
@en
type
label
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
@en
prefLabel
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
@en
P2093
P356
P1433
P1476
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals.
@en
P2093
Matthew D Hall
Natsuho Yamamoto
Timothy W Failes
Trevor W Hambley
P2860
P304
P356
10.1039/B707121C
P407
P577
2007-08-08T00:00:00Z